U.S. Mortgage REITs Stock News

With a price-to-earnings (or "P/E") ratio of 9.4x Regional Management Corp. ( NYSE:RM ) may be sending very bullish...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Kronos Worldwide, Inc. ( NYSE:KRO ) shareholders should be happy to see the share price up 14% in the last week. But...

We'd be surprised if Cryoport, Inc. ( NASDAQ:CYRX ) shareholders haven't noticed that the Independent Director...

Key Insights United States Lime & Minerals' estimated fair value is US$163 based on 2 Stage Free Cash Flow to Equity...

Many CorVel Corporation ( NASDAQ:CRVL ) insiders ditched their stock over the past year, which may be of interest to...

Marten Transport, Ltd. ( NASDAQ:MRTN ) shareholders should be happy to see the share price up 22% in the last month...

In early December 2025, Pacira BioSciences reported results from a 30-patient randomized pilot study comparing its ioveradeg cryoneurolysis to radiofrequency ablation for chronic low back pain, alongside recent FDA clearance of a new Smart tip designed for deeper lumbar nerve access. The combination of encouraging comparative pain data and an FDA-cleared hardware enhancement highlights Pacira’s efforts to broaden ioveradeg’s role across spine-related pain pathways beyond its current...

Vertex (VERX) is back in focus after expanding its long running partnership with CPA.com, rolling out an AI powered sales tax platform built with Kintsugi that aims to streamline compliance work for accounting firms. See our latest analysis for Vertex. Despite this AI push and Vertex’s upcoming presence at the Digital CPA Conference, the stock’s 1 year total shareholder return is deeply negative while the 3 year total shareholder return remains solidly positive. This suggests longer term...

Axogen, Inc. recently announced that the U.S. FDA has approved its Biologics License Application for AVANCE, an acellular nerve scaffold indicated for treating a range of peripheral nerve discontinuities in adults and pediatric patients aged one month and older. This transition of AVANCE to a full biologic regulatory framework, with commercial rollout of the licensed product expected in early second-quarter 2026 while current supply continues under the tissue framework, could materially...

Old National Bancorp (ONB) just caught a tailwind from the Federal Reserve’s latest 25 basis point rate cut, with shares climbing about 5% as investors rotated back into regional banks on easing expectations. See our latest analysis for Old National Bancorp. That Fed driven bounce comes on top of a solid run, with an approximately 10% 1 month share price return and a near 67% five year total shareholder return. This suggests momentum is gradually rebuilding around Old National’s earnings and...

Schneider National (SNDR) has quietly outperformed the market over the past month, climbing about 26%, even as its year to date and 1 year returns remain in negative territory for patient shareholders. See our latest analysis for Schneider National. The recent 30 day share price return of roughly 26 percent, alongside a 12 percent gain over 90 days, suggests momentum is starting to rebuild even though the 1 year total shareholder return is still negative. If Schneider’s rebound has you...

Bragar Eagel & Squire, P.C. is investigating potential claims against Regencell Bioscience Holdings after the company disclosed in October 2025 that it received a U.S. Department of Justice subpoena examining trading in its Ordinary Shares and its operational, financial, and accounting practices. The prospect of significant legal costs, along with possible fines or penalties tied to this broad federal probe, raises material questions about Regencell’s governance, controls, and overall risk...

Earlier this month, Stewards Inc. appointed Scott McGowan as Chief Marketing Officer, tasking him with leading integrated marketing, corporate messaging and investor engagement as the company advances its planned uplisting to the Nasdaq Capital Market. By adding a leader with deep investor relations and growth-transition experience, Stewards is signaling a stronger emphasis on capital-markets readiness and coherent brand positioning across its private credit, real asset and digital finance...

Dyne Therapeutics (DYN) just paired encouraging DELIVER trial data in Duchenne muscular dystrophy with a fresh follow on equity raise, a combination that can reshape both its clinical trajectory and funding runway. See our latest analysis for Dyne Therapeutics. The upbeat DELIVER readout and subsequent capital raise come after a volatile year in which Dyne’s 90 day share price return of 48.34% contrasts with a weaker 1 year total shareholder return of 26.17%. This suggests momentum is...

Ryder System, Inc. has announced that longtime Chairman and CEO Robert E. Sanchez will retire on March 31, 2026, with President and COO John J. Diez set to become CEO and join the board while Sanchez transitions to executive chair to support a phased handover. The elevation of Diez, a veteran leader across Ryder’s finance, fleet management, and dedicated transportation units, signals an emphasis on continuity in the company’s operations and multi-year growth plans rather than an abrupt shift...

FirstEnergy (FE) has quietly outperformed many utility peers over the past year, and that strength is drawing fresh attention as investors reassess defensive stocks in a choppy interest-rate backdrop. See our latest analysis for FirstEnergy. At around $44.26 per share, FirstEnergy’s roughly 11% year to date share price return and robust five year total shareholder return above 80% signal momentum that still looks supported by improving growth and a steadier risk backdrop. If this kind of...

Copart (CPRT) has landed on screens after a mixed setup, with Q1 fiscal 2026 earnings beating EPS expectations but revenue barely growing, while recent analyst commentary highlights insurance related headwinds pressuring sentiment. See our latest analysis for Copart. Despite the solid earnings beat, Copart’s share price has drifted lower to around $38.67. This comes with a steep year to date share price return of roughly negative 31 percent, which contrasts with a still positive three year...

MDU Resources Group recently completed a roughly US$200.0 million follow-on common stock offering and, on December 11, 2025, amended and restated its US$200.0 million revolving credit facility, extending the maturity to December 11, 2030 while keeping existing subfacilities and covenants largely intact. Together, the equity raise and extended credit line reshape MDU’s capital structure by adding fresh equity capital while locking in long-term liquidity and funding flexibility. We’ll now...

If you are wondering whether Advanced Micro Devices is still a smart consideration after its huge multi year run, or if the best days are already priced in, you are in the right place. Even after a recent pullback, with the stock down 4.7% over the last week and 14.6% over the past month, AMD is still up 74.7% year to date and 66.4% over the last year, reflecting a multi year gain of 226.3% over 3 years and 126.1% over 5 years. Recent headlines have focused on AMD's push into AI accelerators...

Earlier this week, Immunovant completed a follow-on equity offering of 26,200,000 common shares at US$21.00 each, raising about US$550.2 million to support operating expenses and a potential commercial launch of IMVT-1402 for Graves’ disease. A distinctive element of the deal is controlling shareholder Roivant Sciences’ decision to purchase a large block of shares, signaling internal support for Immunovant’s expanded IMVT-1402 development plans across multiple autoimmune indications. With...

In recent days, coverage of EMCOR Group has emphasized its lower price-to-earnings ratio relative to Construction & Engineering peers and highlighted upbeat analyst revisions to earnings forecasts. This combination of relatively modest valuation multiples and upgraded growth expectations has sharpened investor attention on how the company is being priced against its outlook. Now, we’ll explore how this renewed focus on EMCOR’s comparatively low P/E ratio may influence its investment...

Nebius Group has recently secured multi‑year AI infrastructure contracts worth about US$17.40 billion with Microsoft and US$2.90 billion with Meta, reinforcing demand for its Nvidia GPU‑powered cloud services even as it contends with heavy data center costs and ongoing net losses. These hyperscaler deals highlight Nebius’ role as a core AI infrastructure provider while intensifying investor focus on whether its aggressive, capital‑intensive capacity buildout and recurring financing needs can...

Preferred Bank recently announced that its Board of Directors approved a 6.7% increase in the annual cash dividend to US$3.20 per share, payable on January 20, 2026 to shareholders of record on January 6, 2026. This higher payout signals management’s confidence in the bank’s capital position and earnings power, and reinforces its emphasis on shareholder returns alongside growth initiatives. We’ll now examine how this higher annual dividend influences Preferred Bank’s investment narrative,...